G. Fraser Et Al. , "Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma," LEUKEMIA , vol.33, no.4, pp.969-980, 2019
Fraser, G. Et Al. 2019. Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. LEUKEMIA , vol.33, no.4 , 969-980.
Fraser, G., Cramer, P., DEMİRKAN, F., Silva, R. S., Grosicki, S., Pristupa, A., ... Janssens, A.(2019). Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. LEUKEMIA , vol.33, no.4, 969-980.
Fraser, G. Et Al. "Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma," LEUKEMIA , vol.33, no.4, 969-980, 2019
Fraser, G. Et Al. "Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma." LEUKEMIA , vol.33, no.4, pp.969-980, 2019
Fraser, G. Et Al. (2019) . "Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma." LEUKEMIA , vol.33, no.4, pp.969-980.
@article{article, author={G. Fraser Et Al. }, title={Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma}, journal={LEUKEMIA}, year=2019, pages={969-980} }